Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic
agent. This 52-week clinical study is designed as an open label, long-term study aimed to
evaluate the safety of vildagliptin in patients with type 2 diabetes.